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ABSTRACT
50- and 30-untranslated regions (UTRs) are important
regulators of gene expression and play key roles in
disease progression and susceptibility. The 50-UTR
of the fragile X mental retardation 1 (FMR1) gene
contains a CGG repeat element that is expanded
(>200 CGG repeats; full mutation) and methylated
in fragile X syndrome (FXS), the most common
form of inherited intellectual disability (ID) and
known cause of autism. Significant phenotypic in-
volvement has also emerged in some individuals
with the premutation (55–200 CGG repeats),
including fragile X-associated premature ovarian
insufficiency (FXPOI) in females, and the neurode-
generative disorder, fragile X-associated tremor/
ataxia syndrome (FXTAS), in older adult carriers.
Here, we show that FMR1 mRNA in human and
mouse brain is expressed as a combination of
multiple isoforms that use alternative transcriptional
start sites and different polyadenylation sites.
Furthermore, we have identified a novel human tran-
scription start site used in brain but not in lymp-
hoblastoid cells, and have detected FMR1 isoforms
generated through the use of both canonical and
non-canonical polyadenylation signals. Importantly,
in both human and mouse, a specific regulation of
the UTRs is observed in brain of FMR1 premutation
alleles, suggesting that the transcript variants may
play a role in premutation-related pathologies.
INTRODUCTION
Fragile X syndrome (FXS) is the most common form of
inherited cognitive impairment, and the most common
single gene mutation associated with autism (1–3). FXS
is caused by a trinucleotide repeat expansion (CGG)n in
the 50-untranslated region (50-UTR) of the fragile X
mental retardation 1 (FMR1) gene located at Xq27.3.
Full mutation CGG-repeat expansions (>200 repeats)
are generally accompanied by methylation-coupled tran-
scriptional silencing of the FMR1 gene, and consequent
absence of the encoded protein (FMRP) (1,4,5).
Substantially diminished or absent FMRP results in
aberrant brain development and function due to the im-
portance of FMRP in synaptic stabilization and plasticity
(2,3,6–8).
Normal alleles have approximately 12–44 CGG repeats;
while premutation alleles have between 55 and 200 CGG
repeats, are typically unmethylated, and usually do not
result in gene inactivation. Over the past several years,
there has been an expanding awareness of the phenotypes
associated with the premutation (1,9,10). Two abnormal
phenotypes specific to premutation alleles have been
described: fragile X-associated premature ovarian
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insufficiency (FXPOI), defined by cessation of menses
prior to age 40 (11,12); and fragile X-associated tremor/
ataxia syndrome (FXTAS), a neurodegenerative disorder
which affects older adult carriers of the FMR1
premutation alleles and is characterized by progressive
cerebellar gait ataxia, intention tremor, cognitive decline
and some psychiatric involvement (9,10,13). In addition,
the most consistent deficits seen in premutation carriers
include shyness, anxiety, social deficits, Attention Deficit
Hyperactivity Disorder (ADHD) and executive function
deficits (14,15).
Although the molecular mechanisms underlying the
premutation pathologies are not well understood, a con-
sistent molecular feature is the elevation of FMR1 mRNA
levels (16–18), as a consequence of an increased rate of
FMR1 transcription (19). However, carriers of premuta-
tion alleles show decreased levels of FMRP (17,20–22),
due to a reduced translational efficiency of FMR1
mRNA containing the expanded CGG repeat (20). These
observations, coupled with the absence of cases of either
FXPOI or FXTAS in the full mutation range (where
protein levels are low–absent), led to the hypothesis that
the premutation-specific disorders are due to an RNA toxic
gain-of-function mechanism (23–25). Additionally, FMR1
mRNA has been detected in the ubiquitin-positive intr-
anuclear inclusions found in neurons and astrocytes
throughout the brain of FXTAS patients (26,27).
A variety of mRNA transcripts arise from a combin-
ation of alternative splicing, alternative transcriptional
start sites selection and differential usage of polyadenyla-
tion sites. In fact, these events generate the vast majority
of diversity of gene expression and have been described
for over 180 000 mouse transcripts (28). Besides alterna-
tive splicing, which can produce extraordinary protein
diversity, regulation at the level of the 50- and 30-UTRs
modulates mRNA processing, nuclear export, stability,
subcellular localization and translational efficiency (29).
Such processes are crucial for differential expression of a
gene during development, tissue differentiation and under
certain pathological conditions (29,30).
In the case of the FMR1 gene, which in human spans
38 Kb of genomic DNA and contains 17 exons (31),
extensive alternative splicing has been demonstrated,
with splicing variants changing during neuronal differen-
tiation both in human and mouse (32–36). In addition,
multiple transcriptional initiation sites, whose distribution
appears to be modulated by the number of CGG repeats,
have been detected in cultured cells from both normal
controls and premutation carriers (37). However, little in-
formation is yet available on the transcription sites and
polyadenylation signal distribution and selection in both
human and mouse tissues.
Thus, it is important to investigate how the variety of
different FMR1 transcripts and splice variants may be
related to protein function and to the clinical phenotype.
Here, we report a detailed study on the structure and dif-
ferential usage of the 50- and 30-UTRs of the FMR1 gene
in both human and mouse brain, showing a different ex-
pression in expanded premutation alleles compared to
normal alleles. In addition, we provide evidence of the
potential role played by the 30-UTR region in translational
regulation of the FMR1 gene, and that could explain, at
least in part, the reduced FMRP levels observed in
premutation alleles.
MATERIALS AND METHODS
Animal care and human tissues
Animal care was conducted in conformance with the in-
stitutional guidelines that are in compliance with Italian
(DL N116, GU, suppl 40, 18-2-1992) and international
laws and policies (European Community Council
Directive 86/609, OJa L 358, 1, December 12, 1987;
National Institutes of Health Guide for the Care and
Use of Laboratory Animals, US National Research
Council, 1996, Belgian law of August 14th, 1986, concern-
ing the protection and well-being of animals, and the fol-
lowing K.B. of November 14th, 1993 and K.B of
September 13th, 2004, concerning the protection of all
laboratory animals, as well as to the European
Community Council Directive 86/609, Oja L 358, 1,
December 12, 1987). All mice (5-months-old CGG
knock-in (KI) and Wild Type (WT) littermates) had a
C57BL/6 genetic background (38).
All studies of ‘post mortem’ human tissue were per-
formed following informed consent in accordance with
University of California, Davis, IRB approved protocols.
RNA isolation
Total RNA was isolated from human brain regions
(cortex, hippocampus and cerebellum) derived from a
subject carrying an FMR1 premutation allele (#334-
03KC, 85 CGG) and from an age matched normal
control (#946,27 CGG). Total RNA was also isolated
from total brain or cerebellum and hippocampus derived
from wild-type (WT) (8 CGG) and CGG KI mice (98
CGG) (38). Isolation of total RNA was performed using
Trizol reagent (Invitrogen) as recommended by the manu-
facturer. Poly(A)+RNAs from the samples were prepared
using the Oligotex mRNA mini kit (Qiagen). The integrity
of the total RNA was checked by monitoring the presence
of intact ribosomal RNAs, 28 S and 18 S using a
Bioanalyzer (Agilent Technologies).
RLM-RACE analysis
50 and 30 RLM-RACE (RNA ligase-mediated rapid ampli-
fication of cDNA ends) analysis was performed on 1 mg of
total RNA from human or mouse tissues using the
Generacer KitTM (Invitrogen), as suggested by the manu-
facturer. Briefly, mRNA was treated with calf intestinal
phosphatase (CIP) to remove the 50 phosphates from any
truncated (i.e. non-capped) mRNA. Dephosphorylated
RNA was treated with tobacco acid pyrophosphatase
(TAP) to remove the 50 cap from full-length mRNA,
leaving a 50 phosphate. The GeneRacerTM RNA oligomer
was then ligated to the 50-end of the mRNA using T7 RNA
ligase. RNA obtained from this step of the 50-RACE
and the total RNA for the 30 reaction were reverse
transcribed using Avian Myeloblastosis Virus Reverse
Transcriptase with the GeneRacerTMoligo-dT primer.
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The regions corresponding to the legitimate 50-ends of
the capped RNA species were PCR amplified from
cDNA templates using the GeneRacerTM 50 primer
(50-CGACTGGAGCACGAGGACACTGA-30) and a
FMR1 gene-specific primer (human, 50-CCTCCACCGG
AAGTGAAACCGAA-30; mouse, 50-TCGCCGTCCGTT
TGCTTCAC-30).
To obtain 30-ends, we amplified the first-strand cDNA
using a FMR1 gene-specific primer (human, 50-CTAAAT
GTTAAAGATGTAGCAAACCCTG-30; mouse 50-GGA
AACGACGATCATTCCCGAACAGA-30) and the
GeneRacerTM 30 Primer (50-GCTGTCAACGATACGCT
ACGTAACG-30).
Cloning and sequencing
PCR products obtained by 50- and 30-RLM-RACE reac-
tions were cloned into pCR 4.1 vector (TA Cloning Kit,
Invitrogen) or into pGEM-T-Easy vector (Promega,
Madison, WI, USA), and ligated products were trans-
fected into One-Shot chemically competent cells
(Invitrogen). Plasmid DNAs were isolated and purified
using plasmid mini kits (Promega), and were screened
for insertions following EcoRI digestion. Positive clones
for each transfection reaction were sequenced by an auto-
mated sequencer (ABI PRISM 310 Genetic Analyzer,
Applied Biosystems) using vector-specific primers. The
number of clones sequenced for each brain region is
indicated for the mouse and human 50-UTRs in Figure
3A and Figure 6A, respectively. The statistical signifi-
cance was assessed by using the Pearson’s chi-square test
(2 test) and the significance level was defined at P-values
<0.05 (*P< 0.05, **P< 0.01, ***P< 0.001).
CGG repeat allele sizing
DNA was isolated from both mouse and human brain
tissue (100mg) using standard conditions (Qiagen) and
analyzed by PCR with oligonucleotide primers specific for
a portion of the Fmr1 genomic DNA sequence flanking
the CGG repeat region. PCR products were separated on
a 6% polyacrylamide sequencing gel and transferred to a
nylon membrane (Roche) and the hybridization was per-
formed with DIG labeled oligonucleotide probe (CGG)8
using conditions as described in (39).
UTRs detection through cDNA circularization and PCR
RNAs isolated from mouse cortex, cerebellum and hippo-
campus were subjected to retrotranscription using
Oligo(dT)12–18 (Invitrogen) and Superscript
TM III RT
(Invitrogen). After removal of the template RNA with
NaOH hydrolysis, the 50-end of the cDNA was phosphor-
ylated using a polynucleotide kinase (New England
Biolabs) and self-ligated using the CircligaseTM II
ssDNA ligase (Epicentre Biotech.), according to manufac-
turer’s instructions. The cDNA was then used as template
to amplify the 30 and 50 ends using a forward primer
(CB378, 50-CCAAGGTAGAATGACCTTGTA-30)
and a reverse primer (CB375, 50-GCGCAGCCCCTCCC
CTTTG-30). The PCR products were analyzed on 2%
agarose gels and the images acquired with a gel scanning
(ImageQuant300, GE Healthcare) using the ImageQuant
software (GE Healthcare). The identity of the PCR
products was assessed by a nested PCR using the
forward primer CB379 (50-GCTCTTGGGCAATATTCT
CTG-30) and sequencing of the product.
Western blotting
Western blotting analysis was performed according to
standard procedures. Briefly, total mouse brain or brain
areas (cortex, hippocampus and cerebellum) from WT
(8 CGG) and CGG KI (98–182 CGG) were homogenized
in Laemmli buffer as described in (40). Proteins from total
brain (10 mg) or from brain areas (5 mg) were loaded onto a
SDS-PAGE gel and transferred on a polyvinylidene
fluoride (PVDF) membrane (Millipore). Membranes
were probed with an anti-FMRP polyclonal antibody
(41) (1:1000), anti-GAPDH (mouse monoclonal,
Chemicon, 1:5000) or anti-Vinculin (mouse monoclonal,
Sigma, 1:2000). The signals were developed using a chemi-
luminescence technique (ECL Basic or Plus, Amersham
Pharmacia) using Fuji film LAS-3000 (Fuji).
Quantification was performed normalizing FMRP levels
to GAPDH using the AIDA software (Raytest
Isotopenmeßgera¨te GmbH). The statistical significance
was assessed by using Student’s t-test and the significance
level was defined at P-values <0.05.
Polyadenylation test (PAT)
The PAT assaywas performed as described in di Penta et al.
(42). Briefly, 1 mg of total RNA extracted as previously
described was tagged by annealing oligo RACE4 (50-GCT
TCAGATCAAGGTGACC(T)12-aminolink) to the end of
the mRNA and extending it with Klenow polymerase
(Roche) at 37C for 60min. The tagged RNAs were
reverse transcribed by SuperscriptTM III RT (Invitrogen)
at 48C for 60min using an oligo similar to RACE4
(CB125, 50-GCTTCAGATCAAGGTGACCTTTTT-30).
The cDNA was then amplified using a forward primer
able to detect the three mRNA species, using the poly(A)
sites IV, V and VI (BMN284, 50-GGTAGAATGACCTTG
TAATGT-30), a forward primer able to detect only the
transcripts containing the poly(A) site VI (CB246, 50-TCT
GAAGATTGTTTATCTTATC-30), or a forward primer
for -actin mRNA (AD48, 50-AGGTGACAGCATTGC
TTCTG-30), and the reverse CB125. As a negative
control, RNAs were deadenylated by incubating with
Oligo(dT)12–18 (Invitrogen) and RNase H (Fermentas) at
37C for 90min, purified by phenol-chloroform and sub-
jected to the same tagging reaction. Graphs shown in
Figure 4B–D were elaborated following a gel scanning
(ImageQuant300, GE Healthcare) using the ImageQuant
software (GE Healthcare).
Polysome/mRNPs gradient
Polysome/mRNPs gradients were performed according to
(40,43,44), with minor modifications. Total mouse brains
from WT (8 CGG) and CGG KI (181–184 CGG) were
homogenized in lysis buffer (10mM NaCl, 10mM MgCl2,
10mM Tris–HCl pH=7.5, 1% Triton X100, 1% DOC,
1mM DTT, 100 mg/mL Cycloheximide, 40 U/ml RNasin).
For the polysome/mRNP analysis of the mRNAs strong
6174 Nucleic Acids Research, 2011, Vol. 39, No. 14
detergent like DOC 1% was used as in (44). These
stringent conditions are only used for RNA analysis.
The lysates were centrifuged 8min at 12 000 g at 4C and
one-fourth of the supernatant was centrifuged through a
5–60% (w/v) sucrose gradient for 135min at 37 000g in a
Beckman SW41 rotor. Each gradient was collected in 11
fractions. RNA was extracted from the fractions and
analyzed by RT-PCR using gene specific primers for
CaMKII mRNA (BMN 190, 50-ACCCTGGCCTGGT
CCTTCAATG-30; BMN 191, 50-AGCCATCCTCACCA
CTATGCTGG-30), -actin mRNA (CD27, 50-AGCAAG
AGAGGTATCCTGACC-30; CD28 50-GCCAATAGTG
ATGACCTGGCC-30), Fmr1 coding sequence mRNA
(BMN 12, 50-GGGTTGGACCTAACTCCTC-30; BMN
13 50- GTCTCTGTGGTCAGATTCTG-30) and Fmr1
isoform VI mRNA (BMN 186, 50- CGTTAAAATATG
CACTAAGTCTC-30; BMN 187 50- GCTTTTTCATAA
GTGCAACTTTTT-30). The amount of template and the
number of amplification cycles were preliminary
optimized for each PCR reaction to avoid saturation as
follows: CaMKII mRNA (Tm=70
C, 35 cycles), -actin
mRNA (Tm=64
C, 35 cycles), Fmr1 coding sequence
mRNA (Tm=60
C, 38 cycles), and Fmr1 isoform VI
mRNA (Tm=60
C, 40 cycles). The PCR products were
analyzed on a 1.2% agarose gel and the images acquired
with a gel scanning (ImageQuant300, GE Healthcare)
using the ImageQuant software (GE Healthcare).
Percentage of messenger on polysome (PMP) was
calculated as described in the ‘Results’ section.
RESULTS
FMR1 mRNA UTR structures in human and mouse brain
The structure of the 50-UTR of FMR1 mRNA has been
studied thus far only in lymphoblastoid cell lines and
primary cultured astrocytes, where the presence of three
transcription start sites (tss) has been reported (37). In
order to study the brain-specific features of the 50-UTR
of the mRNA, we investigated the tss in both human
and mouse brain. For this purpose, we isolated the
50-end of FMR1 mRNA from brain using a 50 RNA
ligase-mediated RACE (RLM-RACE). The resulting
PCR products (four major bands for human and two
for mouse, data not shown) were cloned and sequenced.
As shown in Figure 1, we obtained four tss in human,
three of them corresponding to tss I, II and III previously
identified in lymphoblastoid cells and astrocytes (37), con-
firming and extending earlier findings to brain tissue. In
addition, we identified a novel tss (site IV) located between
the previously identified sites I and II, not identified in
lymphoblastoid cells, suggesting the presence of a novel
start site in brain (Figure 1A–B, marked with an asterisk).
Similarly to sites I, II and III, the new site corresponds to
an Inr-like sequence (consensus YYAN(T/A)YY) (45).
The 50-RLM-RACE analysis performed on mouse
brain, revealed a different functional organization of the
50-UTR. Two tss were detected: site I corresponds to the
human tss III, while mouse start site II is located further
upstream. The nucleotide positions of the two mouse tss
are shown in Figure 1A. A diagram of the human and
mouse 50-UTRs is shown in Figure 1B, while the align-
ment of the promoter region with the position of the dif-
ferent start sites and the relative sequences identified is
shown in Figure 1C.
In addition to tss selection, alternative polyadenylation
strongly contributes to transcript variability; in fact,
almost 50% of human genes have more than one poly-
adenylation site (46,47). Since the structures of human and
mouse FMR1 30-UTRs have not been characterized, we
decided to investigate, via sequence alignment, the
presence of both canonical and non-canonical poly-
adenylation sequences (48). As shown in Figure 2A, we
found eight putative polyadenylation sites in human (I–VI
and a, b); among which only two sites contain the canon-
ical polyadenylation signal represented by the conserved
hexamer AAUAAA (sites IV and a, Figure 2A–B;
asterisk). The other sites are non-canonical and include
the single-nucleotide variant of the consensus sequence
for the first base (UAUAAA, sites I and II) and the
second nucleotide (AUUAAA, sites III, b, V, VI)
(Figure 2B). The alignment between the human and the
murine sequences revealed that six of the eight human sites
were also present in mouse (I–VI), while human sites a and
b were not conserved (Figure 2C). 30-RACE performed on
both human and mouse brain revealed that only three of
the putative poly(A) sites were used in normal brain, spe-
cifically the IV, V, VI (Figures 3B and 6B).
Differential usage of tss and polyadenylation sites in a
mouse model for the premutation
To investigate whether the variants of the mouse Fmr1
mRNA change according to the CGG repeat length, we
took advantage of the mouse model developed to study
triplet instability generated by replacing the murine
(CGG)8 element with a human (CGG)98 repeat
(CGG KI) (38). Since alternative transcriptional start
site usage in the FMR1 gene depends on CGG repeat
size in human lymphoblastoid cell lines and cultured
astrocytes (37), we determined the role of the CGG
repeat length on start site selection in the CGG KI
mouse. For this purpose, we performed a 50-RLM-
RACE on cerebellum and hippocampus; the resulting
PCR products were cloned and sequenced. A total of 24
clones from cerebellum (WT, 16 clones; CGG KI, 8
clones) and 29 clones from hippocampus (WT, 13
clones; CGG KI, 16 clones) were analyzed for the
presence of the two alternative transcriptional start sites
above described (Figure 1 and 3A). A differential usage of
tss I and II was observed in the hippocampus of the CGG
KI mice compared to WT, indicating that in mice, as in
humans, the usage of the different tss appears to be CGG
repeat number dependent. Specifically, the expression of
the short Fmr1 transcript using tss I was higher in WT
compared to CGG KI mouse (44% and 62% in WT cere-
bellum and hippocampus versus 37% and 25% in CGG
KI cerebellum and hippocampus, 2 test, P< 0.05 in the
hippocampus, not significant in cerebellum, P> 0.05)
(Figure 3A). Conversely, Fmr1 mRNAs containing site
II were mostly used in the hippocampus from CGG KI
mice (63% and 75% in the cerebellum and hippocampus
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CGG KI versus 56% and 38% of the corresponding WT
brain regions, 2 test, P< 0.05 in the hippocampus, not
significant in cerebellum, P> 0.05) (Figure 3A).
The structure of the 30-UTR of Fmr1 mRNA and its
expression in premutation alleles are completely unknown.
As mentioned, the in silico analysis revealed six putative
polyadenylation signals in the mouse (Figure 2), while
using the 30-RACE on total brain we could detect only
three of them (Figure 3B). To investigate a possible dif-
ference with normal alleles, we performed a 30-RACE
using total RNA isolated from WT and CGG KI mice
littermates, and cloned and sequenced the PCR products
as previously reported (three major bands, data not
shown). As shown in Figure 3B, two poly(A) sites were
observed in the CGG KI (sites IV and VI). Site IV, the
canonical poly(A) signal, was the most utilized in both
WT and CGG KI mice (78% in WT and 67% in the
CGG KI brain). Site V, which was virtually absent in
the brain from the CGG KI mouse, was detected in WT
although at low levels (11% in WT and no clones in CGG
Figure 1. Structure of the FMR1 50-UTR in human and mouse brain. (A) Nucleotide position of the tss in both human and mouse. The tss are
numbered to the left with respect to the translation codon (+1 ATG, 13967 nt) on a sequence reference (for human access number: L29074: for mouse
access number AY630338). (B) Scheme of the tss in human (I, II, III and IV) and mouse (I and II). The asterisk marks the new tss. (C) Sequence
comparison between human and mouse 50-UTRs. The four human (h site I, II, III and IV) and the two mouse (m sites I and II) tss are bolded, in
black and grey, respectively. The newly identified human transcription start site IV is underlined. The box represents the previously described Internal
Ribosome Entry Site (IRES) (61,62). The alignment was performed using the ClustalW software.
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KI, 2 test, P< 0.05). Differently, site VI was increased in
CGG KI brain (33% in the CGG KI versus 11% in the
WT, 2 test, P< 0.05), possibly suggesting a compensation
mechanism for the absence of the isoform generated with
poly(A) site V.
Additionally, we aimed to study how different 50- and
30-UTRs are assorted in multiple Fmr1 transcripts and
whether this variety changes in premutation alleles. We
applied an approach based on retro-transcription of the
RNA followed by self-ligation of the cDNA. RNAs from
Figure 2. Structure of the FMR1 30-UTR in human and mouse brain. (A) Schematic representation of the putative poly(A) sites, taking into account
both canonical and not-canonical sites (48) in human and mouse. Asterisks mark canonical poly(A) sites. (B) Nucleotide position and consensus
sequence of the poly(A) sites in both human and mouse. (C) Alignment between the regions containing the putative poly(A) signals in human
(accession number NM_002024) and mouse (accession number NM_008031). Consensus sequences are bolded. The alignment was performed using
the ClustalW software.
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Figure 3. Brain specific UTRs in a mouse model for the premutation syndromes. (A) Top panel: Histograms showing the distribution of the two tss
in the cerebellum and hippocampus from WT and CGG KI mice. 2 test, *P< 0.05. Bottom panel: percentage of independent sequenced clones for
WT and CGG KI mice. (B) Top panel: Histograms showing the distribution of the three poly(A) site usage in total brain from WT and CGG KI
mice. 2 test, *P< 0.05. Bottom panel: percentage of independent sequenced clones for WT and CGG KI mice. (C) Left panel: scheme of the
technique used to detect simultaneously the 50- and 30-UTRs from single transcript variants. Briefly, the RNA is retrotranscribed, the cDNA is
self-ligated and the 30 and 50 regions of the circular cDNA amplified by PCR using a forward primer in the 30-UTR and a reverse primer in the
50-UTR. Right panel: nested PCR on the circular cDNAs in cortex, cerebellum and hippocampus from WT and CGG KI mice. M, DNA ladder
(1 kb). (D) Left panel: FMRP expression in total mouse brain from WT (lane 1) and CGG KI (lane 2). Central panel: FMRP levels in cortex,
hippocampus and cerebellum from WT (lanes 1–3) and CGG KI mice (lanes 4–6). Vinculin and GAPDH are used as loading control. Right panel:
quantification of FMRP normalized for GAPDH (n=3, Student’s t-test, *P< 0.05).
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cortex, cerebellum and hippocampus from WT and CGG
KI were retrotranscribed, the cDNA circularized by
ligation and then subjected to PCR using pairs of
primers able to amplify only the circularized cDNA
(Figure 3C, left panel). The resulting PCR products
include both 50- and 30-ends of a single mRNA molecule
joined in the point of ligation (Figure 3C, left panel).
We used several primers downstream the tss I and tss II
as well as upstream poly(A) sites IV and V. Possibly due to
the Fmr1 mRNA structure, only the combination of
primers upstream tss II (CB375) and poly(A) site IV were
able (CB378) to successfully amplify a PCR product cor-
responding to the Fmr1mRNA isoformwith the longest 50-
(tss II) and 30-UTR poly(A) VI (Figure 3C, right panel).
Sequencing assessed the identity of the PCR products. Our
data show that the long 50-UTR was combined with the
long 30-UTR, although we cannot exclude the existence of
other combinations. Of note, the longest UTRs are the
ones that change in CGG KI animals.
The mouse model for the premutation shows reduced
FMRP levels and altered polyadenylation
To understand whether the Fmr1 mRNA variants could
contribute to differential FMRP expression, we measured
the protein levels in different mouse brain regions (com-
paring CGG KI and WT), as well as the polyadenylation
state of different Fmr1 transcripts, which normally reflects
the stability and the translational efficiency of the mRNA
itself.
As previously shown with two different methods
(21,22), FMRP levels were decreased in total brain from
CGG KI compared to WT mice (Figure 3D, left panel).
Moreover, FMRP expression levels were measured in
three brain regions (i.e. cortex, hippocampus and cerebel-
lum) of both CGG KI and WT. A significant decrease
in FMRP expression was detected in both hippocampus
and cerebellum (Figure 3D, central and right panels,
n=3, Student’s t-test, P< 0.05), while no significant
difference was observed in the cortex. Our findings are
in agreement with the observations by Usdin and collab-
orators on another mouse model for the Fragile X
premutation (22) in which a differential deficit of FMRP
in different brain areas was observed. These observations
raise the question whether in premutation carriers clinical
symptoms result from an FMRP deficit in specific brain
regions.
To measure the poly(A) length of the different Fmr1
mRNA isoforms, we used the poly(A) test assay (PAT,
Figure 4A). Briefly, the poly(A) tail of total mRNAs
was tagged as previously described (42) (Figure 4A; see
‘Materials and Methods’ section). The mRNAs were
reverse transcribed and amplified by PCR with a
forward gene-specific primer. Usually, a polyadenylated
mRNA will produce PCR products appearing as a
smear, while the same mRNA which goes through an en-
zymatic shortening of the poly(A) tail (OligodT/RNAse H
treated) produces a single PCR product detected as a
sharp band (Figure 4A, right panel). -Actin mRNA,
known to have a short poly(A) tail (49), was used as
negative control and indeed displayed a polyadenylation
tail within 100 nucleotides (nt) in both WT and CGG KI
(Figure 4B, upper panel, compare lane 1 to lane 2).
To quantify the results, the signal intensity along the
lane was plotted as function of the poly(A) tail length
(Figure 4C, lower panel) and no major changes in the
polyadenylation of -actin mRNA were detected
between WT and CGG KI. Using a gene-specific primer
upstream of site IV, we detected all three variants
(Figure 4B, left panel), although the mRNAs using sites
V and VI could not be distinguished. However, transcripts
using site IV had a poly(A) tail at least up to 250 nt in WT
(Figure 4C, left panel, compare lane 1 and 2, which rep-
resents the control deadenylated mRNA). Poly(A) tails
longer than 250 nt could not be detected due to the
poly(A) interference of isoforms V and VI. The mRNAs
using site IV showed a different distribution between the
two genotypes, with an increased population of short
poly(A) mRNAs (mainly <100 nt) in the CGG KI
compared to WT (Figure 4C, compare lane 3 to 1 in the
left panel and grey to black line in the right panel).
The poly(A) length of transcripts using site V could not
be analyzed because of its close vicinity to site VI. Using
this technique, Fmr1 mRNA generated with the use of
poly(A) site V was detected, although the same mRNA
was not revealed using the cloning strategy, possibly due
to its very low abundance. However, we were able to dis-
criminate the polyadenylation state of transcripts using
site VI, by using a forward primer within sites V and VI.
As shown in Figure 4D, left panel, these mRNAs ex-
hibited a poly(A) tail up to 300 nt (compare lane 1 to 2,
which represents the deadenylated form). As for tran-
scripts using site IV, the polyadenylation state of this
isoform was altered in CGG KI mouse, with an increased
population of short poly(A) mRNAs (mainly <50 nt)
(Figure 4D, left panel, compare lane 3 to 1, right panel,
compare grey to black line). Our findings indicate that the
CGG repeat element affects the polyadenylation of at least
two 30-UTR variants (site IV and VI). Specifically, a re-
duction in the length of the poly(A) tail species was
observed in CGG KI mice. Since it has been widely
reported that poorly polyadenylated mRNAs are not effi-
ciently translated (50,51), the observed difference in
poly(A) tail length could account, at least for a portion,
of the reduced FMRP levels found in premutation alleles
(Figure 3D). In order to verify this hypothesis, we tested
the translational efficiency of the Fmr1mRNA isoforms by
analyzing their partitioning between actively translating
polysomes and silent messenger ribonucleoparticles
(mRNPs) (representative profile, Figure 5A). Brain
extracts from WT and CGG KI mice were fractionated
along a sucrose gradient, RNA was extracted from each
fraction and subjected to RT-PCR analysis as previously
reported (44, 52). As shown in Figure 5B, in WT brain
mRNAs with a high translational efficiency, such as
CaMKII and -actin mRNAs, are predominantly
distributed on heavy polysomes rather than light
mRNPs. Using a gene specific oligo for the Fmr1 coding
sequence (Fmr1 cds), we detected all Fmr1 isoforms
actively translated and associated to polysomes, similarly
to controls (compare to -actin mRNA). To quantify the
efficiency of mRNA translation, we used the percentage of
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Figure 4. Polyadenylation state of Fmr1 mRNA variants in the CGG KI mouse brain. (A) Left panel: schematic view of the polyadenylation assay
(PAT). According to di Penta et al. (42), the poly(A) tails are tagged by incubating the RNA with a (T)12-tag oligonucleotide, blocked at the 3
0-end,
in the presence of dNTPs and Klenow enzyme to fill in the complementary tag sequence. The RNA is then denatured and annealed to a DNA
primer, identical to the tag, to start a reverse transcription (RT). The cDNA is then amplified using a gene-specific forward primer and the reverse
tag oligo. Right panel: cartoon of a polyadenylation profile obtained with a PAT assay. The PCR of a polyadenylated mRNA gives rise to a smear
while the same mRNA deadenylated with oligodT and RNase H prior to poly(A) tagging is used as a negative control and gives a sharp band.
(B) Upper panel: -actin mRNA in WT (lane 1) and CGG KI (lane 3). Deadenylated RNA is shown as negative control (lane 2) and the
deadenylated form is indicated by black arrows. Lower panel: dispersion graph representing the distribution of the -actin polyadenylated transcripts
in WT (black line) and CGG KI (grey line). The signal intensity along the lane has been plotted against the poly(A) tail length, estimated from the
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(continued)
messenger on polysomes (PMP), calculated as the inten-
sity of the signal on polysome fractions over the total. This
analysis showed that Fmr1 mRNA was highly translated,
with a PMP of 65%. In addition, we investigated the
polyadenylation variant VI (Fmr1 VI), which in agreement
with its long poly (A) tail (Figure 4D), was indeed mainly
detected on the polysomes in WT brains (PMP=70%)
(Figure 5B). The same studies performed on the CGG
KI mice (Figure 5C) showed that while the translation
of control mRNAs was comparable between WT and
KI, the translational efficiency of Fmr1 mRNAs (cds)
was reduced in the KI mice (PMP=47% in CGG KI
versus a PMP=65% in WT). Our data confirm and
extend to brain previous reports of an inverse correlation
between translational efficiency and CGG length in
premutation (97–195 CGG) (20), unmethylated full
mutation (400 CGG) (53) and unmethylated full
mutation (266–285 CGG) (54).
Isoform VI, consistent with its shorter poly(A) tail in
the CGG KI mice (Figure 4D), was shifted from poly-
somes to lighter fractions (Figure 5C), indicating a reduc-
tion in its translation efficiency (PMP=25% in CGG KI
versus 70% in WT). Remarkably, in the CGG KI, the
polysome/mRNP distribution of isoform VI changes to
a larger extent compared to all Fmr1 transcripts. All
together, these data indicate that in WT brain the Fmr1
isoform VI contributes mainly to the FMRP synthesis, but
its translation is reduced in the premutation allele,
possibly due to the combinatorial effect of the CGG ex-
pansion and altered polyadenylation. In the CGG KI
allele, specific variants seem to display a different
pattern of regulation compared to WT alleles.
Differential usage of tss and polyadenylation sites in
human premutation carriers
To extend our findings to human brain, we investigated
the structure of both 50 and 30 ends of FMR1 mRNA from
‘post mortem’ brain tissues. 50-RLM-RACE was per-
formed on total RNA isolated from cerebellum and
hippocampus of normal (27 CGG repeats) and pre-
mutation (85 CGG repeats) male subjects. As shown in
Figure 6A, a total of 24 clones from normal cerebellum, 35
from premutation cerebellum, 37 from normal hippo-
campus, and 41 from premutation hippocampus were
sequenced and analyzed for the presence of alternative
tss. In human brain, as well as in lymphoblastoid cell
lines and primary astrocytes (37), the usage of tss
appears to be dependent on the CGG repeat length,
such that in normal FMR1 alleles site I represents the
major transcription start site, at least in cerebellum
(71% in normal cerebellum and 51% in normal hippocam-
pus). This site is selected preferentially in normal cerebel-
lum compared to premutation tissue (71% versus 28%, 2
test, P< 0.01). In contrast, transcripts containing site II
are more abundant in premutation tissues (46% and 44%
in cerebellum and hippocampus from premutation patient
versus 4% and 24% from normal individual, 2 test,
Figure 4. Continued
molecular markers loaded on the same gel. (C) PAT for all three poly(A) Fmr1 mRNA variants. Because of close proximity, the transcripts
containing sites V and VI cannot be discriminated and therefore they are not taken into exam (upper panel). Black arrows points to the deadenylated
form. The polyadenylation of transcripts using site IV from WT (lane 1) and CGG KI (lane 3) has been independently acquired and highlighted in
the box below. Deadenylated RNA treated as mentioned above, is shown as negative control (lane 2). Right panel: dispersion graph for Fmr1
variants using site IV in WT (black line) and CGG KI (grey line). (D) Left panel: PAT for Fmr1 variants using site VI in WT (lane 1) and CGG KI
(lane 3) brain. Deadenylated RNA as above is used as negative control (lane 2). Right panel: Dispersion graph representing the distribution of the
polyadenylated transcripts using site VI in WT (black line) and CGG KI (grey line).
Figure 5. Translational efficiency of Fmr1 mRNA variants in WT and
CGG KI mouse brain. (A) Representative polysome/mRNPs profile,
showing the fractionation of polysomes (P) and light mRNPs
(non-polysomes, NP). The absorbance at 254 nm has been plotted for
11 fractions obtained from a 5–60% sucrose gradient. Ribosomal
subunits 40 S and 60 S, the monomer 80 S and the polyribosomes are
indicated. (B) RT-PCR on the polysome/mRNPs fractions from WT
brains to detect CaMKII, -Actin, Fmr1 coding sequence (cds) and
Fmr1 isoform VI mRNAs. (C) Same as in (B) from the CGG KI mice.
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P< 0.001 and P< 0.05, respectively) (Figure 6A). FMR1
transcripts containing site III were not identified in cere-
bellum and detected at very low level in hippocampus
(both premutation and normal). Interestingly, in lympho-
blasts and astrocytes this site was found to be highly used
in expanded alleles with CGG repeat number in the upper
premutation range (180 CGG repeats) (37), while the
brain premutation sample analyzed here had only 85
CGG repeats. The distribution of site IV did not change
between normal and premutation cerebellum (25% and
26%, respectively), but decreased in the premutation
hippocampus compared to normal (7% versus 22%, 2
test, P< 0.001). It is noteworthy that although the three
initiation sites were also present in premutation alleles,
their distribution was significantly different from the dis-
tribution observed for the normal allele. Moreover, there
was a significant difference in the distribution of site I and
II between normal and premutation alleles (2 test,
P< 0.01 and P< 0.001, respectively) in cerebellum,
demonstrating that the downstream CGG repeat element
influences the start site selection of the FMR1 gene,
extending the previous findings to brain tissue.
Finally, we investigated the structure of the human
FMR1 30-UTR. We compared the poly(A) signal usage
in normal and premutation carriers by sequencing a
total of 54 clones (27 for each condition) (Figure 6B).
Site IV, the canonical poly(A) signal, was predominantly
used compared to the other sites in both alleles (59% in
the normal and 63% in the premutation brain). Site VI
exhibited lower usage than site IV and was comparable for
the two alleles (18.5% in the normal and 22% in the
premutation brain). Interestingly, site V usage was only
detected in normal brain (18.5% of usage) with no
evidence of usage in the premutation tissue (2 test,
P< 0.05). Finally, sites I and II already rarely used in
the premutation brain (4% and 11%, respectively), were
almost not detected in the normal condition (no clones
and 4%, respectively).
DISCUSSION
The UTRs of mRNAs play a critical role in many steps of
post-transcriptional control of gene expression. In fact,
alternative transcripts using different 50- or 30-UTRs
may account for different mRNA stability, translational
efficiency and localization (29). Mutations or perturb-
ations of these regions may alter the RNA interactions
with specific proteins and may shift the physiological
balance from health to disease, resulting in conditions
such as cancer and bipolar affective disorder (30,55).
Mutations in the 50-UTRs, which alter mRNA translation
have been reported to be involved in a number of human
diseases including breast cancer, Alzheimer’s Disease,
Hemoglobin H disease and congenital heart disease
(30,56). These observations support a crucial role of the
UTRs in health and disease (30).
In the current study, we have investigated the structure
of the UTRs of the FMR1 gene responsible for two severe
neurological pathologies, FXS and FXTAS. Through
in silico and RACE analyses, we have characterized
Figure 6. UTRs detection in the human premutation alleles. (A) Top panel: Histograms showing the distribution of the four tss in normal and
premutation alleles in human cerebellum and hippocampus. 2 test, *P< 0.05, **P< 0.01, ***P< 0.001. Bottom panel: Table showing the number of
independent sequenced clones containing the different tss expressed as percentage in the two brain regions analyzed for both normal and premutation
alleles. (B) Top panel: Histograms showing the distribution of the five poly(A) sites identified in normal and premutation alleles in human cerebral
cortex. 2 test, *P< 0.05. Bottom panel: The total number of sequenced clones for the normal and premutation allele is expressed as percentage in
the five poly(A) sites.
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both the 50- and 30-UTRs of FMR1 mRNA in mouse and
human brain with respect to transcription initiation and
to polyadenylation site selection. We found that in
human brain the FMR1 mRNA is expressed as different
isoforms that contain alternative transcriptional start and
polyadenylation sites (Figures 1, 2 and 6). Specifically,
three transcription start sites, previously described in
human cultured cells (37), were also identified in brain
together with a new transcriptional start site (site IV,
Figures 1 and 6A), the latter suggesting the presence of
a brain FMR1 isoform that could account for specific
neuronal functions. These findings were also extended to
the mouse brain, where two sites were identified, the first
one corresponding to a human site and the other located
upstream of the human site III (Figures 1 and 3A). Of
note, both human and mouse FMR1 promoters lack of a
functional TATA box or TATA-like sequences element;
all the tss are located within Inr-like motifs.
Besides the variety generated by the 50-UTR, FMR1
mRNA has three different variants due to the selection
of different polyadenylation signals in the 30-UTR
(Figure 2). The canonical poly(A) (site IV, sequence AA
UAAA) is predominant, while two single-nucleotide
variants of this consensus sequence (sites V and VI) are
less used (Figures 3B and 6B).
To determine whether diverse UTRs play a role in
premutation alleles, we have studied the FMR1 variants in
the brain of CGG KI mice and in ‘post mortem’ brain
tissues from a human premutation carrier. Noteworthy,
the transcript variants change when the CGG triplets are
expanded over the normal threshold, namely in the CGG
KI mouse (Figure 3) and in the premutation carrier
(Figure 6). In both species, the premutation allele favors
the selection of long 50-UTR, indicating that also in
neurons the expanded CGG element affects upstream
transcription events. In the mouse, the longest 50-UTR
variant is more expressed in the hippocampus from
CGG KI compared to WT; in human tissues, the percent-
age of the longest variant (tss III) does not change in
premutation carriers, but this site is rarely used. On the
contrary, in both cerebellum and hippocampus, the other
long variant (site II) is significantly more represented in
premutation carriers, while shorter variants (sites I and IV
in cerebellum and hippocampus, respectively) are less ex-
pressed. Additional variations occur in the 30-UTR of
premutation alleles, where the isoform generated by the
poly(A) site V decreases in both species (Figures 3B
and 6B) and only in human two short variants appear
(Figure 6B). The combination of alternative 50- and
30-UTRs can potentially generate a variety of FMR1 tran-
scripts. Using a method based on self-ligation of single
mRNA species, we could identify at least one variant har-
boring the longest 50- and 30-UTRs (Figure 3C). Evidence
for a direct effect of the CGG expansion on FMR1 trans-
lation efficiency was initially reported in both fibroblast
(54) and lymphoblastoid cell lines (20,53). In particular,
Feng et al. (54) showed that FMR1 mRNAs harboring
an expansion of 266–285 CGG expansion (full muta-
tion range) are associated with stalled 40 S ribosomal
subunits, thus leading to translational inhibition.
Additional effects can arise from other events affecting
mRNA translation, such as polyadenylation (50,51).
Indeed, we found that the premutation has an effect on
the polyadenylation state for at least two Fmr1 mRNA
variants: the transcripts generated using poly(A) site IV
and VI have reduced polyadenylation in the CGG KI
genotype (Figure 4C, D). Since site IV is the most used
in both normal and premutation alleles and site VI is pref-
erentially selected in CGG KI brain, the decreased
polyadenylation of both isoforms could contribute to the
observed reduction of FMRP expression levels observed
in premutation alleles (Figure 3D). Consistently, Fmr1
mRNAs, in particular isoform VI, show an altered
polysome/mRNP distribution in CGG KI brain, suggest-
ing reduced translation efficiency (Figure 5C). Thus, the
overall effect of 50 and 30 variations, including the
expanded CGG element, results in a significant reduction
of FMRP levels in the brain of CGG KI mice, especially in
the cerebellum and the hippocampus (Figure 3D).
The combination of alternative 50- and 30-UTRs in-
creases the complexity of FMR1 expression and the
possible roles of RNA isoforms in neuronal physiology,
as well as in FMR1 related disorders. Alternative FMR1
transcripts generated with different UTRs may account
for differential FMRP expression in various cell types.
FMRP is expressed in both neuron and glia (41,43,57)
and specific FMR1 mRNA isoforms could also be differ-
entially expressed in these two cell types. Intriguingly, the
tss usage seems to display a tissue specificity, with differ-
ences between cerebellum and hippocampus in both
species. This opens the possibility that specific FMR1 tran-
scripts may contribute to a tissue-specific profiling of dif-
ferent neuronal cell types. Furthermore, differential UTR
usage may regulate the FMR1 mRNA translational effi-
ciency. In organisms ranging from viruses to humans,
protein-mediated interactions between transcript termini
result in the formation of an RNA loop. Such RNA ‘cir-
cularization’ is thought to increase translational efficiency
(58). It is tempting to hypothesize that unfavorable com-
bination of different 50-UTRs and 30-UTRs could contrib-
ute to the lower efficiency of translation observed in
premutation alleles (20). Moreover, mRNAs with short
poly(A) tail are translated less efficiently (50,51). Indeed,
the decreased poly(A) tail length of Fmr1 mRNA using
poly(A) site IV and VI points towards the mechanism of
an impaired translation, possibly due to a non-efficient
circularization of the mRNA; consistently, the transcripts
using poly(A) site VI have a reduced translational effi-
ciency in the CGG KI brains. Finally, UTR utilization
is likely to be involved in the correct sub-cellular localiza-
tion of FMR1 mRNA. It has been shown that Fmr1 is
transported along the dendrites (41,59), so alternative
30-UTRs may be involved in its localization to specific
sub-cellular compartments. Interestingly, it has been
shown that Bdnf mRNA containing the longest 30-UTR
is localized at the dendrites and it has a distinct role in
spine morphology and synaptic plasticity (60). Further
studies are required to determine if a differential
sub-cellular localization and function of the alternative
transcripts occur in the FMR1 gene and if it may have a
role in the pathology of FMR1 related disorders including
FXS, FXTAS and FXPOI.
Nucleic Acids Research, 2011, Vol. 39, No. 14 6183
ACKNOWLEDGEMENTS
We thank Tilmann Achsel for his help with the PAT assay
and for critical reading of the manuscript. We are extreme-
ly grateful to Elien Theuns for her support with the
polysome/mRNPs gradients. We are thankful to Katrien
Gobien and Jonathan Royaert for technical help and
Eliane Cherrette´ for assistance.
FUNDING
National Fragile X Foundation (to F.T.); UC Davis
Health System Research Award (to F.T.); National
Institute of Child Health and Human Development
HD02274 (to F.T.). the National Institutes of Health
(HD040661) (to P.J.H.); COFIN-2003 and 2008 (to
C.B.), VIB and Telethon (to C.B.), Associazione Italiana
X Fragile (to S.D.R.), Methusalem grant to Bart De
Strooper (supporting S.D.R. and G.L.F.) VIB. Funding
for open access charge: National Fragile X Foundation
(to F.T.) and VIB (to C.B.). The charges should be
equally divided between F.T. and C.B.
Conflict of interest statement. None declared.
REFERENCES
1. Jacquemont,S., Hagerman,R.J., Hagerman,P.J. and Leehey,M.A.
(2007) Fragile-X syndrome and fragile X-associated tremor/ataxia
syndrome: two faces of FMR1. Lancet Neurol., 6, 45–55.
2. Lightbody,A.A. and Reiss,A.L. (2009) Gene, brain, and behavior
relationships in fragile X syndrome: evidence from neuroimaging
studies. Dev. Disabil. Res. Rev., 15, 343–352.
3. Bassell,G.J. and Warren,S.T. (2008) Fragile X syndrome: loss of
local mRNA regulation alters synaptic development and function.
Neuron, 60, 201–214.
4. Pieretti,M., Zhang,F.P., Fu,Y.H., Warren,S.T., Oostra,B.A.,
Caskey,C.T. and Nelson,D.L. (1991) Absence of expression of the
FMR-1 gene in fragile X syndrome. Cell, 66, 817–822.
5. Verkerk,A.J., Pieretti,M., Sutcliffe,J.S., Fu,Y.H., Kuhl,D.P.,
Pizzuti,A., Reiner,O., Richards,S., Victoria,M.F., Zhang,F.P.
et al. (1991) Identification of a gene (FMR-1) containing a CGG
repeat coincident with a breakpoint cluster region exhibiting
length variation in fragile X syndrome. Cell, 65, 905–914.
6. De Rubeis,S. and Bagni,C. (2010) Fragile X mental retardation
protein control of neuronal mRNA metabolism: Insights into
mRNA stability. Mol. Cell Neurosci., 43, 43–50.
7. Zukin,R.S., Richter,J.D. and Bagni,C. (2009) Signals, synapses,
and synthesis: how new proteins control plasticity. Front Neural.
Circuits, 3, 14.
8. Pfeiffer,B.E. and Huber,K.M. (2009) The state of synapses in
fragile X syndrome. Neuroscientist, 15, 549–567.
9. Hagerman,P.J. and Hagerman,R.J. (2004) The fragile-X
premutation: a maturing perspective. Am. J. Hum. Genet., 74,
805–816.
10. Bourgeois,J.A., Coffey,S.M., Rivera,S.M., Hessl,D., Gane,L.W.,
Tassone,F., Greco,C., Finucane,B., Nelson,L., Berry-Kravis,E.
et al. (2009) A review of fragile X premutation disorders:
expanding the psychiatric perspective. J. Clin. Psychiatry, 70,
852–862.
11. Allingham-Hawkins,D.J., Babul-Hirji,R., Chitayat,D., Holden,J.J.,
Yang,K.T., Lee,C., Hudson,R., Gorwill,H., Nolin,S.L.,
Glicksman,A. et al. (1999) Fragile X premutation is a significant
risk factor for premature ovarian failure: the International
Collaborative POF in Fragile X study–preliminary data.
Am. J. Med. Genet., 83, 322–325.
12. Toniolo,D. and Rizzolio,F. (2007) X chromosome and ovarian
failure. Semin. Reprod. Med., 25, 264–271.
13. Berry-Kravis,E., Abrams,L., Coffey,S.M., Hall,D.A., Greco,C.,
Gane,L.W., Grigsby,J., Bourgeois,J.A., Finucane,B.,
Jacquemont,S. et al. (2007) Fragile X-associated tremor/ataxia
syndrome: clinical features, genetics, and testing guidelines.
Mov. Disord., 22, 2018–2030.
14. Cornish,K.M., Kogan,C., Turk,J., Manly,T., James,N., Mills,A.
and Dalton,A. (2005) The emerging fragile X premutation
phenotype: evidence from the domain of social cognition.
Brain Cogn., 57, 53–60.
15. Farzin,F., Perry,H., Hessl,D., Loesch,D., Cohen,J., Bacalman,S.,
Gane,L., Tassone,F., Hagerman,P. and Hagerman,R. (2006)
Autism spectrum disorders and attention-deficit/hyperactivity
disorder in boys with the fragile X premutation.
J. Dev. Behav. Pediatr., 27, S137–S144.
16. Tassone,F., Hagerman,R.J., Taylor,A.K., Gane,L.W.,
Godfrey,T.E. and Hagerman,P.J. (2000) Elevated levels of FMR1
mRNA in carrier males: a new mechanism of involvement in the
fragile-X syndrome. Am. J. Hum. Genet., 66, 6–15.
17. Kenneson,A., Zhang,F., Hagedorn,C.H. and Warren,S.T. (2001)
Reduced FMRP and increased FMR1 transcription is
proportionally associated with CGG repeat number
in intermediate-length and premutation carriers.
Hum. Mol. Genet., 10, 1449–1454.
18. Allen,E.G., He,W., Yadav-Shah,M. and Sherman,S.L. (2004) A
study of the distributional characteristics of FMR1 transcript
levels in 238 individuals. Hum. Genet., 114, 439–447.
19. Tassone,F., Beilina,A., Carosi,C., Albertosi,S., Bagni,C., Li,L.,
Glover,K., Bentley,D. and Hagerman,P.J. (2007) Elevated FMR1
mRNA in premutation carriers is due to increased transcription.
RNA, 13, 555–562.
20. Primerano,B., Tassone,F., Hagerman,R.J., Hagerman,P.,
Amaldi,F. and Bagni,C. (2002) Reduced FMR1 mRNA
translation efficiency in fragile X patients with premutations.
RNA, 8, 1482–1488.
21. Brouwer,J.R., Huizer,K., Severijnen,L.A., Hukema,R.K.,
Berman,R.F., Oostra,B.A. and Willemsen,R. (2008) CGG-repeat
length and neuropathological and molecular correlates in a
mouse model for fragile X-associated tremor/ataxia syndrome.
J. Neurochem., 107, 1671–1682.
22. Entezam,A., Biacsi,R., Orrison,B., Saha,T., Hoffman,G.E.,
Grabczyk,E., Nussbaum,R.L. and Usdin,K. (2007) Regional
FMRP deficits and large repeat expansions into the full mutation
range in a new Fragile X premutation mouse model. Gene, 395,
125–134.
23. Brouwer,J.R., Willemsen,R. and Oostra,B.A. (2009) The FMR1
gene and fragile X-associated tremor/ataxia syndrome.
Am. J. Med. Genet. B Neuropsychiatr. Genet., 150B, 782–798.
24. Garcia-Arocena,D. and Hagerman,P.J. (2010) Advances
in understanding the molecular basis of FXTAS.
Hum. Mol. Genet., 19, R83–R89.
25. Tan,H., Li,H. and Jin,P. (2009) RNA-mediated pathogenesis in
fragile X-associated disorders. Neurosci. Lett., 466, 103–108.
26. Tassone,F., Iwahashi,C. and Hagerman,P.J. (2004) FMR1 RNA
within the intranuclear inclusions of fragile X-associated tremor/
ataxia syndrome (FXTAS). RNA Biol., 1, 103–105.
27. Greco,C.M., Hagerman,R.J., Tassone,F., Chudley,A.E., Del
Bigio,M.R., Jacquemont,S., Leehey,M. and Hagerman,P.J. (2002)
Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia
syndrome among fragile X carriers. Brain, 125, 1760–1771.
28. Carninci,P., Kasukawa,T., Katayama,S., Gough,J., Frith,M.C.,
Maeda,N., Oyama,R., Ravasi,T., Lenhard,B., Wells,C. et al.
(2005) The transcriptional landscape of the mammalian genome.
Science, 309, 1559–1563.
29. Mignone,F., Gissi,C., Liuni,S. and Pesole,G. (2002) Untranslated
regions of mRNAs. Genome Biol., 3, REVIEWS0004.
30. Chatterjee,S. and Pal,J.K. (2009) Role of 50- and
30-untranslated regions of mRNAs in human diseases. Biol. Cell,
101, 251–262.
31. Eichler,E.E., Richards,S., Gibbs,R.A. and Nelson,D.L. (1993)
Fine structure of the human FMR1 gene. Hum. Mol. Genet., 2,
1147–1153.
32. Sittler,A., Devys,D., Weber,C. and Mandel,J.L. (1996) Alternative
splicing of exon 14 determines nuclear or cytoplasmic localisation
of fmr1 protein isoforms. Hum. Mol. Genet., 5, 95–102.
6184 Nucleic Acids Research, 2011, Vol. 39, No. 14
33. Ashley,C.T., Sutcliffe,J.S., Kunst,C.B., Leiner,H.A., Eichler,E.E.,
Nelson,D.L. and Warren,S.T. (1993) Human and murine FMR-1:
alternative splicing and translational initiation downstream of the
CGG-repeat. Nat. Genet., 4, 244–251.
34. Verheij,C., Bakker,C.E., de Graaff,E., Keulemans,J.,
Willemsen,R., Verkerk,A.J., Galjaard,H., Reuser,A.J.,
Hoogeveen,A.T. and Oostra,B.A. (1993) Characterization and
localization of the FMR-1 gene product associated with fragile X
syndrome. Nature, 363, 722–724.
35. Huang,T., Li,L.Y., Shen,Y., Qin,X.B., Pang,Z.L. and Wu,G.Y.
(1996) Alternative splicing of the FMR1 gene in human fetal
brain neurons. Am. J. Med. Genet., 64, 252–255.
36. Xie,W., Dolzhanskaya,N., LaFauci,G., Dobkin,C. and
Denman,R.B. (2009) Tissue and developmental regulation of
fragile X mental retardation 1 exon 12 and 15 isoforms.
Neurobiol. Dis., 35, 52–62.
37. Beilina,A., Tassone,F., Schwartz,P.H., Sahota,P. and
Hagerman,P.J. (2004) Redistribution of transcription start
sites within the FMR1 promoter region with expansion of
the downstream CGG-repeat element. Hum. Mol. Genet., 13,
543–549.
38. Bontekoe,C.J., Bakker,C.E., Nieuwenhuizen,I.M., van der
Linde,H., Lans,H., de Lange,D., Hirst,M.C. and Oostra,B.A.
(2001) Instability of a (CGG)98 repeat in the Fmr1 promoter.
Hum. Mol. Genet., 10, 1693–1699.
39. Tassone,F., Pan,R., Amiri,K., Taylor,A.K. and Hagerman,P.J.
(2008) A rapid polymerase chain reaction-based screening method
for identification of all expanded alleles of the fragile X (FMR1)
gene in newborn and high-risk populations. J. Mol. Diagn., 10,
43–49.
40. Napoli,I., Mercaldo,V., Boyl,P.P., Eleuteri,B., Zalfa,F., De
Rubeis,S., Di Marino,D., Mohr,E., Massimi,M., Falconi,M. et al.
(2008) The fragile X syndrome protein represses
activity-dependent translation through CYFIP1, a new 4E-BP.
Cell, 134, 1042–1054.
41. Ferrari,F., Mercaldo,V., Piccoli,G., Sala,C., Cannata,S., Achsel,T.
and Bagni,C. (2007) The fragile X mental retardation
protein-RNP granules show an mGluR-dependent localization in
the post-synaptic spines. Mol. Cell. Neurosci., 34, 343–354.
42. di Penta,A., Mercaldo,V., Florenzano,F., Munck,S., Ciotti,M.T.,
Zalfa,F., Mercanti,D., Molinari,M., Bagni,C. and Achsel,T. (2009)
Dendritic LSm1/CBP80-mRNPs mark the early steps of transport
commitment and translational control. J. Cell Biol., 184, 423–435.
43. Zalfa,F., Giorgi,M., Primerano,B., Moro,A., Di Penta,A., Reis,S.,
Oostra,B. and Bagni,C. (2003) The fragile X syndrome protein
FMRP associates with BC1 RNA and regulates the translation of
specific mRNAs at synapses. Cell, 112, 317–327.
44. Bagni,C., Mannucci,L., Dotti,C.G. and Amaldi,F. (2000)
Chemical stimulation of synaptosomes modulates alpha -Ca2+/
calmodulin-dependent protein kinase II mRNA association to
polysomes. J. Neurosci., 20, RC76.
45. Javahery,R., Khachi,A., Lo,K., Zenzie-Gregory,B. and Smale,S.T.
(1994) DNA sequence requirements for transcriptional initiator
activity in mammalian cells. Mol. Cell. Biol., 14, 116–127.
46. Yan,J. and Marr,T.G. (2005) Computational analysis of 30-ends
of ESTs shows four classes of alternative polyadenylation in
human, mouse, and rat. Genome Res., 15, 369–375.
47. Tian,B., Mukhopadhyay,R. and Mathews,M.B. (2005)
Polymorphic CUG repeats in human mRNAs and their effects on
gene expression. RNA Biol., 2, 149–156.
48. Sheets,M.D., Ogg,S.C. and Wickens,M.P. (1990) Point mutations
in AAUAAA and the poly (A) addition site: effects on the
accuracy and efficiency of cleavage and polyadenylation in vitro.
Nucleic Acids Res., 18, 5799–5805.
49. Meijer,H.A., Bushell,M., Hill,K., Gant,T.W., Willis,A.E., Jones,P.
and de Moor,C.H. (2007) A novel method for poly(A)
fractionation reveals a large population of mRNAs with a short
poly(A) tail in mammalian cells. Nucleic Acids Res., 35, e132.
50. Gallie,D.R. (1991) The cap and poly(A) tail function
synergistically to regulate mRNA translational efficiency.
Genes Dev., 5, 2108–2116.
51. Sonenberg,N. and Dever,T.E. (2003) Eukaryotic translation
initiation factors and regulators. Curr. Opin. Struct. Biol., 13,
56–63.
52. Gu,W., Pan,F. and Singer,R.H. (2009) Blocking beta-catenin
binding to the ZBP1 promoter represses ZBP1 expression, leading
to increased proliferation and migration of metastatic
breast-cancer cells. J. Cell Sci., 122, 1895–1905.
53. Pietrobono,R., Tabolacci,E., Zalfa,F., Zito,I., Terracciano,A.,
Moscato,U., Bagni,C., Oostra,B., Chiurazzi,P. and Neri,G. (2005)
Molecular dissection of the events leading to inactivation of the
FMR1 gene. Hum. Mol. Genet., 14, 267–277.
54. Feng,Y., Zhang,F., Lokey,L.K., Chastain,J.L., Lakkis,L.,
Eberhart,D. and Warren,S.T. (1995) Translational suppression by
trinucleotide repeat expansion at FMR1. Science, 268, 731–734.
55. Lopez de Silanes,I., Quesada,M.P. and Esteller,M. (2007)
Aberrant regulation of messenger RNA 30-untranslated region in
human cancer. Cell Oncol., 29, 1–17.
56. Pickering,B.M. and Willis,A.E. (2005) The implications of
structured 50 untranslated regions on translation and disease.
Semin. Cell Dev. Biol., 16, 39–47.
57. Wang,H., Ku,L., Osterhout,D.J., Li,W., Ahmadian,A., Liang,Z.
and Feng,Y. (2004) Developmentally-programmed FMRP
expression in oligodendrocytes: a potential role of FMRP in
regulating translation in oligodendroglia progenitors.
Hum. Mol. Genet., 13, 79–89.
58. Mazumder,B., Seshadri,V. and Fox,P.L. (2003) Translational
control by the 30-UTR: the ends specify the means.
Trends Biochem. Sci., 28, 91–98.
59. Antar,L.N., Dictenberg,J.B., Plociniak,M., Afroz,R. and
Bassell,G.J. (2005) Localization of FMRP-associated mRNA
granules and requirement of microtubules for activity-dependent
trafficking in hippocampal neurons. Genes Brain Behav., 4,
350–359.
60. An,J.J., Gharami,K., Liao,G.Y., Woo,N.H., Lau,A.G.,
Vanevski,F., Torre,E.R., Jones,K.R., Feng,Y., Lu,B. et al. (2008)
Distinct role of long 30 UTR BDNF mRNA in spine morphology
and synaptic plasticity in hippocampal neurons. Cell, 134,
175–187.
61. Chiang,P.W., Carpenter,L.E. and Hagerman,P.J. (2001) The
50-untranslated region of the FMR1 message facilitates
translation by internal ribosome entry. J. Biol. Chem., 276,
37916–37921.
62. Dobson,T., Kube,E., Timmerman,S. and Krushel,L.A. (2008)
Identifying intrinsic and extrinsic determinants that regulate
internal initiation of translation mediated by the FMR1 50 leader.
BMC Mol. Biol., 9, 89.
Nucleic Acids Research, 2011, Vol. 39, No. 14 6185
